Hookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short Interest

Hookipa Pharma Inc (NASDAQ:HOOK) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 39,500 shares, an increase of 9.1% from the October 31st total of 36,200 shares. Currently, 0.6% of the shares of the company are sold short. Based on an average trading volume of 42,700 shares, the short-interest ratio is currently 0.9 days.

Hookipa Pharma Trading Down 1.2 %

Shares of NASDAQ HOOK opened at $2.55 on Wednesday. The business has a 50-day moving average of $3.53 and a 200-day moving average of $5.20. The firm has a market capitalization of $30.75 million, a price-to-earnings ratio of -0.69 and a beta of 0.71. Hookipa Pharma has a 12 month low of $2.08 and a 12 month high of $11.30.

Hedge Funds Weigh In On Hookipa Pharma

A number of institutional investors have recently made changes to their positions in HOOK. Virtu Financial LLC bought a new stake in shares of Hookipa Pharma during the 1st quarter worth $31,000. Renaissance Technologies LLC raised its position in Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after purchasing an additional 83,800 shares in the last quarter. Ikarian Capital LLC bought a new stake in Hookipa Pharma during the third quarter worth about $228,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after purchasing an additional 108,844 shares in the last quarter. Institutional investors own 63.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on HOOK shares. JMP Securities lowered their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, November 21st. Royal Bank of Canada dropped their price target on Hookipa Pharma from $50.00 to $48.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.